CRM1-IN-2 (Compound KL2) is a noncovalent inhibitor that targets CRM1, localizing it to the nuclear periphery, depleting its nuclear presence, and inhibiting its nuclear export function. It demonstrates the capability to inhibit the growth of colorectal cancer cells and induce apoptosis [1].